Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | APP | P05067 | 1/20 | 0.54 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19849358 | 0.88 | MEN1 (0.52) | POLBMEN1KMT2AKDM4ELMNA | |
| SCHEMBL20879965 | 0.87 | MEN1 (0.54) | POLBMEN1KMT2AKDM4ELMNA | |
| SCHEMBL18588486 | 0.84 | KDM4E (0.49) | POLBMEN1KMT2AKDM4ELMNA | |
| SCHEMBL24333908 | 0.84 | NPSR1 (0.56) | POLBMEN1KMT2ANPSR1ALDH1A1 | |
| SCHEMBL13164061 | 0.84 | NPSR1 (0.59) | POLBMEN1KMT2ANPSR1ALDH1A1 | |
| SCHEMBL18588483 | 0.83 | MEN1 (0.51) | POLBMEN1KMT2AKDM4ELMNA | |
| SCHEMBL26506323 | 0.83 | MEN1 (0.53) | POLBMEN1KMT2AKDM4ELMNA | |
| SCHEMBL21883952 | 0.83 | NPSR1 (0.52) | POLBMEN1KMT2ANPSR1APP | |
| SCHEMBL21347710 | 0.83 | POLB (0.55) | POLBMEN1KMT2AKDM4ENPSR1 | |
| SCHEMBL13164063 | 0.83 | NPSR1 (0.58) | POLBMEN1KMT2AKDM4ENPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8022222-B2 | Glucokinase activators | ARRAY BIOPHARMA, INC. (US) | 2011-09-20 | — | — | US | disclosed |
| US-20090247526-A1 | GLUCOKINASE ACTIVATORS | ARRAY BIOPHARMA INC. (US) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247526-A1 | GLUCOKINASE ACTIVATORS | GCKR, GCK, GALK1 | POLB 2674/4885MEN1 3595/4885KMT2A 2715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.